CA3225964A1 - Polynucleotide and pharmaceutical composition - Google Patents
Polynucleotide and pharmaceutical composition Download PDFInfo
- Publication number
- CA3225964A1 CA3225964A1 CA3225964A CA3225964A CA3225964A1 CA 3225964 A1 CA3225964 A1 CA 3225964A1 CA 3225964 A CA3225964 A CA 3225964A CA 3225964 A CA3225964 A CA 3225964A CA 3225964 A1 CA3225964 A1 CA 3225964A1
- Authority
- CA
- Canada
- Prior art keywords
- acg
- acc
- moe
- nucleotides
- acu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021109239 | 2021-06-30 | ||
| JP2021-109239 | 2021-06-30 | ||
| JP2021-169846 | 2021-10-15 | ||
| JP2021169846 | 2021-10-15 | ||
| PCT/JP2022/026411 WO2023277168A1 (ja) | 2021-06-30 | 2022-06-30 | ポリヌクレオチド及び医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3225964A1 true CA3225964A1 (en) | 2023-01-25 |
Family
ID=84692765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3225964A Pending CA3225964A1 (en) | 2021-06-30 | 2022-06-30 | Polynucleotide and pharmaceutical composition |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240325426A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4365288A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023277168A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240026181A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022302611A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3225964A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023277168A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024185697A1 (ja) * | 2023-03-03 | 2024-09-12 | 国立大学法人東海国立大学機構 | ポリヌクレオチド連結産物の製造方法 |
| WO2025111430A1 (en) * | 2023-11-21 | 2025-05-30 | Prime Medicine, Inc. | CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL |
| WO2026010855A1 (en) * | 2024-07-02 | 2026-01-08 | Trilink Biotechnologies, Llc | Modified rna for increasing protein expression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01114346A (ja) | 1987-10-26 | 1989-05-08 | Seiko Electronic Components Ltd | 冷却ファン付モータ |
| EP1021549A2 (en) * | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
| WO2009135212A2 (en) * | 2008-05-02 | 2009-11-05 | Epicentre Technologies Corporation | Selective 5' ligation tagging of rna |
| US10086043B2 (en) * | 2011-04-03 | 2018-10-02 | The General Hospital Corporation | Efficient protein expression in vivo using modified RNA (MOD-RNA) |
| JP5678022B2 (ja) | 2012-10-31 | 2015-02-25 | 京セラドキュメントソリューションズ株式会社 | 画像形成装置及び画像形成プログラム |
| EP3434774A1 (en) * | 2013-01-17 | 2019-01-30 | ModernaTX, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| US20170202979A1 (en) * | 2014-07-17 | 2017-07-20 | Modernatx, Inc. | Terminal modifications of polynucleotides |
| JP6275576B2 (ja) | 2014-07-24 | 2018-02-07 | ヤンマー株式会社 | 作業車輌 |
| EP3177732A4 (en) | 2014-08-08 | 2018-04-25 | ModernaTX, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
| WO2016100812A1 (en) * | 2014-12-19 | 2016-06-23 | Moderna Therapeutics, Inc. | Terminal modifications of polynucleotides |
| SMT202500412T1 (it) | 2016-01-11 | 2025-11-10 | Innate Tumor Immunity Inc | Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro |
| KR20220122701A (ko) * | 2019-12-26 | 2022-09-02 | 내셔널 유니버시티 코포레이션 토카이 내셔널 하이어 에듀케이션 앤드 리서치 시스템 | 폴리뉴클레오티드 및 의약 조성물 |
-
2022
- 2022-06-30 KR KR1020247001879A patent/KR20240026181A/ko active Pending
- 2022-06-30 JP JP2023532082A patent/JPWO2023277168A1/ja active Pending
- 2022-06-30 WO PCT/JP2022/026411 patent/WO2023277168A1/ja not_active Ceased
- 2022-06-30 CA CA3225964A patent/CA3225964A1/en active Pending
- 2022-06-30 AU AU2022302611A patent/AU2022302611A1/en active Pending
- 2022-06-30 US US18/575,623 patent/US20240325426A1/en active Pending
- 2022-06-30 EP EP22833314.2A patent/EP4365288A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240026181A (ko) | 2024-02-27 |
| EP4365288A4 (en) | 2025-03-12 |
| EP4365288A1 (en) | 2024-05-08 |
| WO2023277168A1 (ja) | 2023-01-05 |
| US20240325426A1 (en) | 2024-10-03 |
| AU2022302611A1 (en) | 2024-02-15 |
| JPWO2023277168A1 (cg-RX-API-DMAC7.html) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6757373B2 (ja) | キラルデザイン | |
| AU2022302611A1 (en) | Polynucleotide and medicinal composition | |
| JP7667775B2 (ja) | ヌクレオチド類似体を含有するオリゴヌクレオチド | |
| JP6613143B2 (ja) | 2’ヌクレオシド間結合を含有する低分子干渉核酸(siNA)分子 | |
| JP2022512975A (ja) | S-抗原輸送阻害オリゴヌクレオチドポリマーおよび方法 | |
| US20100081627A1 (en) | Polymeric nucleoside prodrugs | |
| AU2023268503A1 (en) | Oligonucleotide compositions and methods thereof | |
| AU2017315670A1 (en) | Compositions comprising reversibly modified oligonucleotides and uses thereof | |
| KR20150036642A (ko) | 키랄 제어 | |
| EP3762395A1 (en) | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | |
| CA2465129A1 (en) | Acyclic linker-containing oligonucleotides and uses thereof | |
| EP4082579A1 (en) | Polynucleotide and medicinal composition | |
| US20090069263A1 (en) | 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof | |
| JP2976436B2 (ja) | 新規オリゴリボヌクレオチド誘導体及び抗ウイルス剤への使用 | |
| CN117769598A (zh) | 多核苷酸及医药组合物 | |
| WO2008025160A1 (en) | Oxepane nucleosides and oligonucleotides, uses thereof and methods of making the same | |
| CN113490742A (zh) | 膦酰基乙酸酯缺口聚物寡核苷酸 | |
| WO2025264952A2 (en) | Novel rna therapeutics and uses thereof | |
| WO2025172372A1 (en) | Conjugate for targeted delivery of an antisense oligonucleotide | |
| HK40088424A (en) | Chiral design | |
| HK40091261B (en) | Oligonucleotide for 5'-capped rna synthesis | |
| JPWO1996018640A1 (ja) | アンチセンス核酸同族体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250506 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250506 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260505 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260505 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260629 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260629 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260727 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260727 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260727 |